What question did this study set out to answer?

To evaluate the tumor specificity and efficacy of the KIR-based CAR T cell therapy SynKIR-110 targeting mesothelin in comparison to conventional treatments.

November 25, 2025The Journal of ImmunologyOpen Access

Improved Tumor Specificity of Mesothelin (MSLN)-specific Killer Immunoglobulin Receptor (KIR)-based Chimeric Antigen Receptor (CAR) T cell therapy SynKIR-110 3562

View Full Paper

Ask AI

Bookmark

Authors

NNNora Nora YYYucel YUCEL TTTam Truong

Discussion

Member takes

Implication

This work demonstrates improved tumor specificity of mesothelin-targeting CAR T cell therapy, suggesting enhanced potential in tumor immunology.

Key Points

To evaluate the tumor specificity and efficacy of the KIR-based CAR T cell therapy SynKIR-110 targeting mesothelin in comparison to conventional treatments.
Comparison of SynKIR-110 with SS1-41BBz CAR T cell therapy
Assessment of T cell growth and phenotype
Evaluation of co-culture cytokine levels and tumor lysis in MSLN-positive and MSLN-negative targets
SynKIR-110 exhibited 4-fold higher T cell growth compared to SS1-41BBz
Observed 4-fold lower CAR MFI expression and 6-fold lower 41BB+% at baseline
Both therapies showed similar effectiveness in eliminating MSLN+ targets, but SynKIR-110 had less basal killing against MSLN- targets

Cite This Study

Nora et al. (2025) studied this question.

synapsesocial.com/papers/692502d187af00ed34ac28f0 https://doi.org/10.1093/jimmun/vkaf283.1353

View Full Paper

Ask AI

Bookmark

Implication

This work demonstrates improved tumor specificity of mesothelin-targeting CAR T cell therapy, suggesting enhanced potential in tumor immunology.

Improved Tumor Specificity of Mesothelin (MSLN)-specific Killer Immunoglobulin Receptor (KIR)-based Chimeric Antigen Receptor (CAR) T cell therapy SynKIR-110 3562

Discussion

Member takes

Implication

Key Points

Cite This Study

Improved Tumor Specificity of Mesothelin (MSLN)-specific Killer Immunoglobulin Receptor (KIR)-based Chimeric Antigen Receptor (CAR) T cell therapy SynKIR-110 3562

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider